Provided by Tiger Fintech (Singapore) Pte. Ltd.

KALA BIO

5.10
+0.05000.99%
Post-market: 5.100.00000.00%15:44 EDT
Volume:54.94K
Turnover:286.58K
Market Cap:32.91M
PE:-0.67
High:5.38
Open:5.05
Low:5.05
Close:5.05
Loading ...

Romulus K. Brazzell, Officer, Reports Disposal of Common Shares of Kala Bio Inc

Reuters
·
27 Jun

Kala Bio Inc. Officer Romulus K. Brazzell Reports Disposal of Common Shares

Reuters
·
05 Jun

KALA BIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
23 May

Kala Pharmaceuticals price target lowered to $12 from $15 at H.C. Wainwright

TIPRANKS
·
23 May

Kala Bio Q1 EPS $(1.41) Beats $(2.03) Estimate

Benzinga
·
14 May

Kala Bio Inc. Reports Q1 2025 Financials: Decrease in G&A and R&D Expenses, Cash Resources Expected to Fund Operations into 2026

Reuters
·
14 May

BRIEF-Kala Bio Q1 EPS USD -1.41

Reuters
·
14 May

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
14 May

KALA BIO Q1 EPS USD -1.41

THOMSON REUTERS
·
14 May

KALA BIO Inc expected to post a loss of $2.03 a share - Earnings Preview

Reuters
·
09 May

Kala Pharmaceuticals (KALA) Receives a Buy from Oppenheimer

TIPRANKS
·
14 Apr

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

KALA BIO Advances Eye Disease Therapies with New Funding

TIPRANKS
·
01 Apr

Kala Bio Q4 EPS $(1.74) Beats $(2.28) Estimate

Benzinga
·
31 Mar

BRIEF-Kala Bio Q4 EPS USD -1.74

Reuters
·
31 Mar

KALA BIO Q4 Income From Operations USD -9.459 Million

THOMSON REUTERS
·
31 Mar

KALA BIO Q4 EPS USD -1.74

THOMSON REUTERS
·
31 Mar

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
31 Mar

KALA BIO Inc expected to post a loss of $2.28 a share - Earnings Preview

Reuters
·
25 Mar

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
26 Feb